Technical Analysis for GLYC - GlycoMimetics, Inc.

Grade Last Price % Change Price Change
grade D 3.66 -2.92% -0.11
GLYC closed down 2.92 percent on Wednesday, February 26, 2020, on 1.22 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical GLYC trend table...

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Signal Line Cross Bearish -2.92%
Stochastic Reached Oversold Weakness -2.92%
BB Squeeze Ended Range Expansion -2.92%
Below Lower BB Weakness -2.92%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases. Its lead product includes GMI-1070, a glycomimetic drug candidate that acts as a pan-selectin antagonist has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The company is also developing GMI-1271, a specific E-selectin antagonist, which it plans to initiate a Phase I dose-escalation clinical trials in healthy volunteers to be used in combination with chemotherapy to treat acute myeloid leukemia and potentially other hematologic cancers. In addition, its drug candidates comprise GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Gaithersburg, Maryland.
Biotechnology Health Pharmaceutical Industry Diseases Drug Discovery Chemotherapy Clinical Trial Acute Myeloid Leukemia Design Of Experiments Product Testing Sickle Cell Disease Pseudomonas Hematologic Cancers Nursing Research

Is GLYC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 13.56
52 Week Low 2.64
Average Volume 189,576
200-Day Moving Average 6.63
50-Day Moving Average 4.80
20-Day Moving Average 4.23
10-Day Moving Average 4.11
Average True Range 0.22
ADX 38.79
+DI 8.15
-DI 39.27
Chandelier Exit (Long, 3 ATRs ) 3.97
Chandelier Exit (Short, 3 ATRs ) 4.23
Upper Bollinger Band 4.63
Lower Bollinger Band 3.82
Percent B (%b) -0.2
BandWidth 19.19
MACD Line -0.25
MACD Signal Line -0.22
MACD Histogram -0.0302
Fundamentals Value
Market Cap 119.77 Million
Num Shares 32.7 Million
EPS -1.34
Price-to-Earnings (P/E) Ratio -2.73
Price-to-Sales 18873.21
Price-to-Book 3.02
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.05
Resistance 3 (R3) 4.06 3.94 3.99
Resistance 2 (R2) 3.94 3.84 3.94 3.96
Resistance 1 (R1) 3.80 3.78 3.74 3.79 3.94
Pivot Point 3.68 3.68 3.65 3.68 3.68
Support 1 (S1) 3.54 3.58 3.48 3.53 3.38
Support 2 (S2) 3.42 3.52 3.42 3.36
Support 3 (S3) 3.28 3.42 3.34
Support 4 (S4) 3.27